One Molecule, Two Jobs: SOTIO's Cancer Immunocytokine Patent Confirmed by EPO
💡 Cytune Pharma (a SOTIO Biotech affiliate), AP-HP, INSERM, and Université Paris Cité hold European Patent EP 3 444 271 B1 - "IL-15 and IL-15Rα Sushi Domain Based Modulokines." The EPO Boards of Appeal upheld it on 21 July 2026, defeating oppositions from Sanofi SA and Strawman Limited. The patent covers a new cancer drug format called a modulokine: a single protein that fuses an IL-15 superagonist with an anti-PD-1 antibody, pressing the immune accelerator and removing the cancer's brake at the same time.
What EP 3 444 271 B1 actually protects
The patent covers a new class of biological drugs called modulokines - engineered fusion proteins that link an interleukin-15 (IL-15) superagonist, stabilized by the "sushi domain" of the IL-15 receptor alpha subunit, to an immunomodulatory antibody targeting PD-1. The antibody component targets the same checkpoint as Keytruda (pembrolizumab) and Opdivo (nivolumab). The structural difference is fundamental: in a modulokine, both functions are built into one molecule, not two separate drugs given as parallel infusions.
The patent was filed on 8 August 2014, with a priority date of 8 August 2013. The EPO granted it on 6 October 2021. Sanofi SA and Strawman Limited then mounted legal oppositions - formal challenges before the EPO - arguing the claims lacked novelty or inventive step. The EPO Boards of Appeal reviewed those challenges and, on 21 July 2026, confirmed the patent valid in full. Protection runs to August 2034. The claims cover immunocytokine compositions, the nucleic acids encoding them, production methods in CHO cells, and pharmaceutical formulations for reactivating tumor-infiltrating lymphocytes (TILs) in cancer patients.
The clinical product built on this IP is SOT201, SOTIO Biotech's lead compound. It entered the clinic in May 2024 through the Phase 1 VICTORIA-01 study (NCT06163391), run at MD Anderson Cancer Center plus European sites in Belgium, the Czech Republic, and Spain. Early data show "a high disease control rate, including objective responses in heavily pre-treated patients." Understanding why those responses happen requires understanding a fundamental gap in today's standard treatment.
The checkpoint inhibitor gap: why one drug is not enough
PD-1 checkpoint inhibitors are among the most significant medical advances of the past decade. By blocking PD-1, they prevent cancer cells from silencing tumor-reactive T cells. In some patients, the result is dramatic and durable remission. Yet the majority of patients with solid tumors do not respond, or relapse after initial response. Two structural reasons explain this.
First, cold tumors: many solid tumors contain very few T cells in their microenvironment. Removing the PD-1 brake has nothing to accelerate if no T cells are present. Second, T cell exhaustion: in tumors with infiltrating T cells, chronic antigen exposure causes those cells to become functionally depleted. They display PD-1 as a marker of that exhaustion. Removing the PD-1 signal can partially restore function, but exhausted T cells have lost key transcriptional programs and need active cytokine support to become fully cytotoxic again. This is where IL-15 enters the picture.
IL-15 is a cytokine that drives the activation, proliferation, and memory of CD8+ cytotoxic T cells and natural killer (NK) cells - the immune system's primary tumor killers. Systemic IL-15 has shown anti-tumor activity in clinical trials, but it also activates immune cells throughout the body, generating serious toxicity. The engineering challenge is to deliver IL-15 precisely to the tumor-resident T cells that need it. The sushi domain is the solution.
The sushi domain: a precision cytokine delivery system
IL-15 is unusual among cytokines in how it signals. It does not bind its receptor and signal directly. Instead, IL-15 must first be loaded onto IL-15 receptor alpha (IL-15Rα) on a presenting cell, then trans-presented to IL-15 receptor beta/gamma on a neighboring T cell or NK cell. The sushi domain is the smallest protein fragment of IL-15Rα that retains this IL-15 binding and stabilizing function. When IL-15 is fused to the sushi domain in a single recombinant protein, the result is a superagonist: significantly more potent and stable than free IL-15, because it arrives pre-loaded and ready to trans-signal.
The modulokine in EP 3 444 271 B1 fuses this IL-15 superagonist to an anti-PD-1 antibody. The antibody seeks out PD-1-positive T cells - which, in the tumor microenvironment, are precisely the exhausted CD8+ cells most likely to be found at the cancer site. When the antibody binds PD-1, it simultaneously blocks the inhibitory signal and delivers the IL-15 superagonist to that exact cell. This "cis-acting" design is the core invention: the cytokine activation goes to the cell the antibody finds, not to every immune cell in the bloodstream. In preclinical models comparing SOT201 to separate anti-PD-1 plus free IL-15, the modulokine showed superior T cell reactivation and tumor-killing activity. SOTIO describes it as "one of the first IL-15/PD-1 targeting immunocytokines," and the EPO confirmed that novelty holds up under adversarial scrutiny.
Why Sanofi's challenge failed - and what the EPO decision means
Sanofi's opposition to EP 3 444 271 B1 was commercially motivated and technically serious. Sanofi markets Cemiplimab (LIBTAYO), its own anti-PD-1 drug for skin cancer and NSCLC. A broad, valid patent covering anti-PD-1 immunocytokines as a drug class constrains Sanofi's freedom to develop next-generation modulokine formats that build on PD-1 antibody technology. Oppositions at the EPO are expensive, time-consuming, and require expert technical arguments. Sanofi filed one anyway. The EPO Boards of Appeal reviewed the challenges and upheld the patent in full on 21 July 2026, finding the claims novel, inventive, and sufficiently disclosed.
For SOTIO, the confirmation secures IP through August 2034 - a window covering the anticipated commercialization period of SOT201 if Phase 2 and 3 trials succeed. It also establishes the modulokine format as a patentably distinct design space, signaling to other companies filing in this area that foundational claims are occupied. For the field, the decision confirms that bispecific cytokine-checkpoint fusion proteins are patentable when the cis-acting mechanism is clearly demonstrated - a precedent that will shape IP strategy across the immunocytokine sector for years.
| Parameter | Value |
|---|---|
| Patent number | EP 3 444 271 B1 |
| Title | IL-15 and IL-15Rα Sushi Domain Based Modulokines |
| Assignees | Cytune Pharma SAS / AP-HP / INSERM / Univ. Paris Cité |
| Inventors | Alain Gey, Eric Tartour, David Bechard |
| Priority date | 8 August 2013 |
| EPO grant date | 6 October 2021 |
| EPO appeal upheld | 21 July 2026 |
| Jurisdiction | European Patent Office |
| Clinical product | SOT201 / VICTORIA-01 (NCT06163391) |
| Patent expires | August 2034 |
Who is threatened, and what this patent could unlock
The competitive implications spread across the checkpoint inhibitor market - projected to reach USD 154.3 billion by 2030 from USD 49.8 billion in 2026. Merck's Keytruda franchise, with over USD 25 billion in 2024 sales, faces a patent cliff in the late 2020s. BMS's Opdivo (nivolumab) and Roche/Genentech's atezolizumab (Tecentriq) face the same exposure. If SOT201 or a next-generation modulokine demonstrates meaningfully better response rates in head-to-head trials, the shift from single-checkpoint antibodies to cytokine-checkpoint fusions could be rapid and commercially significant.
The broader IL-15 validation is already underway. The IL-15 superagonist complex N-803 (ANKTIVA, ImmunityBio) received accelerated FDA approval for bladder cancer in 2024, and in January 2026 it received accelerated approval for metastatic NSCLC in combination with a checkpoint inhibitor. This is the "IL-15 + checkpoint" concept executed as two separate drugs; SOT201 does it in one molecule. Several other companies are developing related IL-15 fusion proteins - ImmunGene, COVA Biosciences, and MedImmune (AstraZeneca) have filed in this space. The confirmation of EP 3 444 271 B1 sets the foundational claim boundaries they must design around.
Three pathways that this IP could unlock: (1) solid tumors historically resistant to checkpoint inhibitors - such as pancreatic or microsatellite-stable colorectal cancers - where IL-15's T cell recruiting effect might open immunologically silent tumors; (2) combinations with CAR-T cell therapy, where IL-15 has shown the ability to expand and sustain engineered T cells in vivo; and (3) a path toward replacing two-drug infusion regimens with a single molecule - simpler to manufacture, to dose, and to translate across regulatory jurisdictions. That translation, both linguistic and legal, is where the story connects to patent translation.
What it means for us: precision translation for precision medicine
EP 3 444 271 B1 is a European patent, but "European patent" does not mean a single uniform protection. After the EPO grants a patent, the holder must validate it individually in each country where protection is sought. Validation in France, Germany, or most EPO member states that have not signed the London Agreement requires translation of patent claims or specifications into the national language. A modulokine patent contains molecular biology claims, protein sequence references, cell culture production methods, and pharmaceutical formulation claims. Every claim is a precise legal statement - one mistranslated term can leave a gap in coverage that a competitor can exploit.
Beyond Europe, Vietnam is an increasingly active pharmaceutical market with growing PCT filings; national-phase entry in Vietnam requires a Vietnamese translation of the patent specification. As the immunocytokines market alone is projected to reach USD 5.37 billion by 2030 - growing at 37.3% per year (Roots Analysis, 2025) - the volume of complex biotech patent specifications requiring accurate IP translation and technical translation into Vietnamese and other languages will grow in parallel. SOT201's patent journey, from a French university lab in 2013 to a confirmed European IP asset in 2026, is one clear illustration of why that translation work matters.
FAQ
What is an immunocytokine, and how is it different from a checkpoint inhibitor?
An immunocytokine is a fusion protein combining a cytokine (an immune-activating signal protein) with an antibody. A checkpoint inhibitor is just an antibody that removes an inhibitory signal. An immunocytokine like SOT201 does both at once: it removes the PD-1 brake AND delivers an IL-15 activation signal to the same T cell - in a single molecule.
What does the sushi domain do in this patent?
The sushi domain is the smallest functional fragment of the IL-15 receptor alpha subunit (IL-15Rα). When fused to IL-15, it stabilizes the cytokine and pre-loads it into its "ready-to-signal" configuration. The result is an IL-15 superagonist - far more potent and durable than free IL-15 - that can be precisely targeted by attaching it to an antibody.
What did the EPO Boards of Appeal decide on 21 July 2026?
The EPO Boards of Appeal upheld European Patent EP 3 444 271 B1 in full, rejecting oppositions filed by Sanofi SA and Strawman Limited. The Board found the patent's claims to be novel, inventive, and sufficiently disclosed. IP protection runs to August 2034 for Cytune Pharma, AP-HP, INSERM, and Université Paris Cité.
Is SOT201 already approved for cancer treatment?
Not yet. SOT201 is in Phase 1 clinical trials (VICTORIA-01, NCT06163391) for advanced solid tumors. Early data show promising disease control and objective responses in heavily pre-treated patients, but regulatory approval requires successful Phase 2 and Phase 3 trials and a regulatory submission process.
Why does patent translation matter for biotech patents like this one?
European patents must be validated country by country; most countries require a national-language translation of the claims or full specification. Biotech patents like EP 3 444 271 B1 contain precise molecular biology language - protein sequences, cell culture methods, formulation claims - where a single mistranslation can create a legal gap in protection. Specialist patent translation with both scientific and linguistic expertise is essential for full IP enforcement.
Sources
GlobeNewsWire: EPO confirms EP 3 444 271 B1 (July 21, 2026) · Google Patents: EP3444271B1 · SOTIO: SOT201 pipeline · Roots Analysis: Immunocytokines market, 2025 · ClinicalTrials.gov: NCT06163391 (VICTORIA-01) · GM Insights: Checkpoint inhibitors market, 2026
About the author
Dao Huy (Lucas) is a professional translator with over 7 years of experience specializing in technical translation, patent translation, and IP translation from English, Chinese, and French into Vietnamese. His work spans complex biotech, pharmaceutical, and engineering patent specifications - precisely the depth that a patent like EP 3 444 271 B1 requires when filing or enforcing across multiple jurisdictions.
If your IP portfolio includes biotech, pharmaceutical, or engineering patents that need accurate English to Vietnamese technical translation, patent translation, or technology localization into Vietnamese, contact Dao Huy for a quote at daohuy.com.
Written by Dao Huy (Lucas), Vietnamese translator & localization specialist (EN · ZH · FR → Vietnamese). See translation services →